Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
The invention relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. It has been found that compositions combining a statin and a cannabinoid are improved over existing statin formulations. The compositions of the invention for example allow for a lower effective dose of statin and a reduction of the adverse effects seen with statins taken alone. Dosing ranges and formulations suitable for oral, buccal, and sublingual administration are disclosed. Various specific cannabinoids such as cannabidiol and synthetic cannabidiols selected for their anti-inflammatory, antioxidant, and anti-atherosclerotic effect are shown to be particularly advantageous.
1. A pharmaceutical composition in unit dosage form for once daily dosing, useful in treating a patient with a lipid disorder, which consists essentially of a statin-cannabidiol combination of:
(a) a reduced daily dosage amount of a statin; and
(b) less than or equal to 500 mg of a cannabidiol;
together with a pharmaceutically acceptable carrier, diluent, or excipient; wherein the reduced daily dosage amount of the statin is less than the lowest standard daily dosage amount for the statin when taken alone; and wherein the pharmaceutical composition is formulated for oral or mucosal administration and the statin-cannabidiol combination confers a synergistic effect compared to the statin and the cannabidiol administered alone in the same amounts, said synergistic effect responsible for the reduced daily dosage amount of the statin without loss of therapeutic effect, and wherein the statin is atorvastatin.
2. The pharmaceutical composition of claim 1 , wherein the atorvastatin is present in the unit dosage form in an amount of between 5-10 mg.
3. The pharmaceutical composition of claim 1 , wherein the atorvastatin is present in the unit dosage form in an amount of between 2-5 mg.
4. The pharmaceutical composition of claim 1 , wherein the statin is present in the unit dosage form in an amount of between 1-2 mg.
5. The pharmaceutical composition of claim 1 , wherein the atorvastatin is present in the unit dosage form in an amount of less than 1 mg.
6. The pharmaceutical composition of claim 1 , wherein the unit dosage form is suitable for oral administration, and atorvastatin and the cannabidiol both undergo first-pass metabolism after administration.
7. The pharmaceutical composition of claim 1 , wherein the unit dosage form is suitable for buccal or sublingual administration.
8. A pharmaceutical composition for once daily dosing, useful in treating a patient with a lipid disorder, which consists essentially of a statin-cannabidiol combination of therapeutically effective amounts of:
(a) a reduced daily dosage amount of a statin; and
(b) a cannabidiol;
wherein the reduced daily dosage amount of the statin is less than the lowest standard daily dosage amount for the statin when taken alone; and wherein the pharmaceutical composition is formulated for oral or mucosal administration and the statin-cannabidiol combination confers a synergistic effect compared to the statin and the cannabidiol administered alone in the same amounts, said synergistic effect responsible for the reduced daily dosage amount of the statin without loss of therapeutic effect, and wherein the statin is atorvastatin.
9. The pharmaceutical composition of claim 8 , wherein the reduced daily dosage amount of the atorvastatin is no greater than 50% of the lowest standard daily dosage amount for the atorvastatin when taken alone.
10. The pharmaceutical composition of claim 8 , wherein the reduced daily dosage amount of atorvastatin is no greater than 25% of the lowest standard daily dosage amount for atorvastatin when taken alone.
11. The pharmaceutical composition of claim 8 , wherein the atorvastatin and the cannabidiol are both substrates of the same CYP enzyme, and the atorvastatin and the cannabidiol both undergo first-pass metabolism after administration by said CYP enzyme.
12. The pharmaceutical composition of claim 8 , wherein the cannabidiol has been selected for greater affinity for a CYP enzyme.
13. A method of treating a medical condition in a human in need of such treatment, the method comprising administering in combination to the human a synergistically and therapeutically effective amount of atorvastatin and a cannabidiol, and wherein the medical condition is selected from the group consisting of a dysregulation of cholesterol metabolism, myositis, rhabdomyolysis, and statin-associated myopathy.
14. The method of claim 13 wherein the medical condition is hypercholesterolemia.
15. The method of claim 13 wherein the medical condition is atherosclerosis.